0001426332 2022-04-26 2022-04-26 0001426332 8-K/A true 2022-04-26 NGM Biopharmaceuticals, Inc. DE 001-38853 26-1679911 333 Oyster Point Boulevard South San Francisco CA 94080 650 243-5555 false false false false Common Stock, par value $0.001 per share NGM NASDAQ false On March 10, 2022, NGM Biopharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing that, on March 10, 2022, the Company received notice from Fidelity Investments Institutional Services Company (“Fidelity”) advising of an upcoming blackout period (the “Blackout Period”) with respect to the NGM Biopharmaceuticals Matching Plan and the NGM Biopharmaceuticals 401(k) Plan (respectively, the “Matching Plan” and the “401(k) Plan”), each of which include funds that are invested in the Company’s common stock, due to the merger of the Matching Plan into the 401(k) Plan. The Company also disclosed in the Original Form 8-K that the Blackout Period was expected to end on May 13, 2022.This Amendment No. 1 to the Original Form 8-K (“Amendment”) is being filed solely to disclose that, on April 26, 2022, the Company received notice from Fidelity that the Blackout Period ended earlier than expected.Other than providing the update in Item 5.04 below, no updates have been made to the Original Form 8-K. Accordingly, this Amendment should be read in conjunction with the Original Form 8-K.